Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620722 | 0.89 | SIGMAR1 (0.51) | TSHRALDH1A1CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL7623544 | 0.82 | OPRM1 (0.49) | CYP2D6KMT2ASIGMAR1MC4RCCR3 | |
| SCHEMBL7628106 | 0.81 | LMNA (0.64) | ALDH1A1CYP2D6KMT2AMAPK1LMNA | |
| SCHEMBL7625247 | 0.79 | SIGMAR1 (0.56) | TSHRALDH1A1KMT2ASIGMAR1MC4R | |
| SCHEMBL7623444 | 0.77 | SIGMAR1 (0.55) | TSHRALDH1A1KMT2ASIGMAR1MC4R | |
| SCHEMBL4610975 | 0.77 | TSHR (0.80) | TSHRALDH1A1CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL6602340 | 0.76 | SIGMAR1 (0.53) | TSHRALDH1A1KMT2ASIGMAR1HTR1A | |
| Hydrochloric Acid SCHEMBL6504677 | 0.76 | TSHR (0.78) | TSHRALDH1A1CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL7628069 | 0.75 | CYP2D6 (0.49) | TSHRALDH1A1CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL3392742 | 0.75 | TSHR (0.43) | TSHRKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | TSHR 3032/4885ALDH1A1 2557/4885CYP2D6 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.